Abstract
In patients with esophageal squamous cell carcinoma (ESCC) who have residual disease in both the tumor and lymph nodes (ypT+N+) after neoadjuvant immunochemotherapy (NICT) and radical surgery, adjuvant immunotherapy (AIT) significantly reduces recurrence and death. This real-world study suggests that while AIT improves disease-free survival (DFS) and overall survival (OS) for this high-risk subgroup, it may not provide a significant benefit for the overall cohort or those achieving a pathological complete response.
Introduction
Esophageal cancer remains a global health challenge with a high risk of recurrence even after radical surgery. While neoadjuvant chemoradiotherapy (NCRT) followed by surgery is a standard of care, neoadjuvant immunochemotherapy (NICT)—combining immunotherapy with chemotherapy before surgery—has emerged as a potent new treatment mode.
The landmark CheckMate 577 trial established that adjuvant immunotherapy (AIT) benefits patients with residual disease after NCRT. However, it remained unclear whether patients who receive the newer NICT regimen also require AIT after surgery. Clinicians face a dilemma: should every patient get post-operative immunotherapy, or can we spare those who have already responded well to the initial treatment?
Methods
Researchers conducted a retrospective analysis of 215 patients with ESCC who underwent NICT followed by radical esophagectomy at Zhejiang Cancer Hospital between 2019 and 2020.
Patients received two cycles of NICT (various PD-1 inhibitors plus chemotherapy) followed by surgery. The study compared patients who received AIT (n=78) versus those who did not (n=137). Survival was measured using Disease-Free Survival (DFS) and Overall Survival (OS), with patients stratified by pathological response: ypT0N0 (complete response), ypT+N0 (residual tumor but no nodal involvement), and ypT+N+ (residual disease in both).
Key Results and Discussion
Overall Cohort Outcomes
For the entire cohort of 215 patients, the 3-year DFS was 62.3% and the 3-year OS was 74.0%. Interestingly, when comparing the AIT and non-AIT groups across the whole population, no statistically significant difference was observed (P=0.984 for DFS; P=0.384 for OS).
The "High-Risk" Signal: ypT+N+ Subgroup
The benefit of AIT was concentrated in the ypT+N+ subgroup—patients whose cancer persisted in both the primary site and the lymph nodes despite neoadjuvant treatment. For these high-risk individuals, AIT acted as a critical "mop-up" phase:
- 3-Year DFS: Improved from 23.9% (no AIT) to 38.5% (with AIT) (P=0.036).
- 3-Year OS: Improved from 37.0% (no AIT) to 61.5% (with AIT) (P=0.010).
- Hazard Ratios: AIT was associated with a significantly lower risk of recurrence (HR: 0.297) and death (HR: 0.321) in this group.
Diminishing Returns for Pathological Complete Response (pCR)
Patients who achieved a pathological complete response (ypT0N0) had excellent outcomes regardless of whether they received AIT. This suggests that for "deep responders," the toxicity and cost of additional immunotherapy might not be justified.
Distant vs. Local Recurrence
AIT was particularly effective at reducing distant recurrence (14.1% vs. 27.7%, P=0.022) rather than local recurrence, highlighting its role in controlling systemic micrometastasis.
Conclusion
This real-world study advocates for "Precision Over Prophylaxis." AIT is not a "one-size-fits-all" solution but a targeted win for high-risk ypT+N+ patients. While these results are promising, the authors emphasize that large-scale Randomized Controlled Trials (RCTs) are necessary to confirm these findings and formally establish AIT as a standard for the ypT+N+ subgroup after NICT.
Summary updated